PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective

In the past two decades, extensive efforts have been made to develop agents targeting prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To date, represented by two recent approvals of [(68)Ga]Ga-PSMA-11 and [(18)F]F-DCFPyL by the United States Food and Drug Administr...

Descripción completa

Detalles Bibliográficos
Autores principales: Debnath, Sashi, Zhou, Ning, McLaughlin, Mark, Rice, Samuel, Pillai, Anil K., Hao, Guiyang, Sun, Xiankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835702/
https://www.ncbi.nlm.nih.gov/pubmed/35163083
http://dx.doi.org/10.3390/ijms23031158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835702/
https://www.ncbi.nlm.nih.gov/pubmed/35163083
http://dx.doi.org/10.3390/ijms23031158

Ejemplares similares